Fused heterocyclic organic compounds and uses thereof

A pharmaceutical formulation comprising a compound of Formula II or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, wherein Formula II comprises:

• wherein:
• R1 is —(C2-C6 alkylidene)-NR6R7, —(C2-C6 alkylidene)-X1—(C2-C6 alkylidene)-NR6R7, or —(C3-C6 cycloalkylidene)-NR6R7, and is optionally substituted with one or more groups independently selected from C1-C6 alkyl, C3-C6 cycloalkyl, halogen, —OH, alkoxy, —NO2, amino, —CN, —COOH, —COOR8, and amido;
• R2, R3, R4, and R5 are independently selected from H, halogen, —CN, amino, —NO2, C1-C6 alkyl, C3-C6 cycloalkyl, alkoxy, —(C1-C6 alkylidene)-X2—(C1-C6 alkyl), aryl, heterocyclyl, heteroaryl, aralkyl, and heterocyclylalkyl, and are optionally substituted with one or more groups independently selected from C1-C6 alkyl, C3-C6 cycloalkyl, halogen, —OH, alkoxy, —NO2, amino, —CN, —COOH, —COOR9, and amido;
• X1 and X2 are independently selected from null, —O—, —S—, —SO2—, —(C═O)—, —N(R11)—, and —C(O)N(R12)—, and are optionally substituted with one or more groups independently selected from halogen, —OH, amino, alkoxy, —CN, and —NO2;
• R6 and R7 are independently selected from —H, C1-C6 alkyl, and C3-C6 cycloalkyl;
• or R6, R7 and the nitrogen to which they are attached join together to form a heterocyclic ring,
• R8, R9, R10, and R11 are independently selected from H, C1-C6 alkyl, and C3-C6 cycloalkyl, and R10 is H, C1-C6 alkyl, C3-C6 cycloalkyl, or halogen.

A pharmaceutical formulation comprising a compound of Formula III or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, wherein Formula III comprises:

• wherein:
• R1 is —(C2-C6 alkylidene)-NR6R7, —(C2-C6 alkylidene)-X1—(C2-C6 alkylidene)-NR6R7, or —(C3-C6 cycloalkylidene)-NR6R7, and is optionally substituted with one or more groups independently selected from C1-C6 alkyl, C3-C6 cycloalkyl, halogen, —OH, alkoxy, —NO2, amino, —CN, —COOH, —COOR8, and amido;
• R2, R3, and R4 are independently selected from H, halogen, —CN, amino, —NO2, C1-C6 alkyl, C3-C6 cycloalkyl, alkoxy, —(C1-C6 alkylidene)-X2—(C1-C6 alkyl), aryl, heterocyclyl, heteroaryl, aralkyl, and heterocyclylalkyl, and are optionally substituted with one or more groups independently selected from C1-C6 alkyl, C3-C6 cycloalkyl, halogen, —OH, alkoxy, —NO2, amino, —CN, —COOH, —COOR9, and amido;
• X1 and X2 are independently selected from null, —O—, —S—, —SO2—, —(C═O)—, —N(R11)—, and —C(O)N(R12)—, and are optionally substituted with one or more groups independently selected from halogen, —OH, amino, alkoxy, —CN, and —NO2;
• R6 and R7 are independently selected from H, C1-C6 alkyl, and C3-C6 cycloalkyl;
• or R6, R7 and the nitrogen to which they are attached join together to form a heterocyclic ring, and
• R8, R9, R10, and R11 are independently selected from H, C1-C6 alkyl, and C3-C6 cycloalkyl.

A pharmaceutical formulation comprising a compound of Formula IV or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, wherein Formula IV comprises:

• wherein:
• R1 is —(C2-C6 alkylidene)-NR6R7, —(C2-C6 alkylidene)-X1—(C2-C6 alkylidene)-NR6R7, or —(C3-C6 cycloalkylidene)-NR6R7, and is optionally substituted with one or more groups independently selected from C1-C6 alkyl, C3-C6 cycloalkyl, halogen, —OH, alkoxy, —NO2, amino, —CN, —COOH, —COOR8, and amido,
• R2, R3, and R4 are independently selected from H, halogen, —CN, amino, —NO2, C1-C6 alkyl, C3-C6 cycloalkyl, alkoxy, —(C1-C6 alkylidene)-X2—(C1-C6 alkyl), aryl, heterocyclyl, heteroaryl, aralkyl, and heterocyclylalkyl, and are optionally substituted with one or more groups independently selected from C1-C6 alkyl, C3-C6 cycloalkyl, halogen, —OH, alkoxy, —NO2, amino, —CN, —COOH, —COOR9, and amido,
• X1 and X2 are independently selected from null, —O—, —S—, —SO2—, —(C═O)—, —N(R11)—, and —C(O)N(R12)—, and are optionally substituted with one or more groups independently selected from halogen, —OH, amino, alkoxy, —CN, and —NO2,
• R6 and R7 are independently selected from H, C1-C6 alkyl, and C3-C6 cycloalkyl;
• or R6, R7 and the nitrogen to which they are attached join together to form a heterocyclic ring,
• R8 , R9, R10, and R11 are independently selected from H, C1-C6 alkyl, and C3-C6 cycloalkyl, and
• R10 is H, C1-C6 alkyl, C3-C6 cycloalkyl, or halogen.